NEW DELHI: Intas Pharmaceuticals has launched its first biosimilar product, Accofil, used in treating immune system disorders, in European markets. The company has launched its first biosimilar, ...

The product has recently been introduced under the brand Accofil and has already won two tenders, in Netherlands and the UK Intas Pharmaceuticals has launched their first biosimilar, filgrastim, in ...

Accofil is a biosimilar product of Neupogen (filgrastim) and will offer patients cost effective therapy that is comparable in quality, safety and efficacy. Accofil is indicated for the treatment of ...

LONDON – The EMA added an eighth product to the roster of biosimilar versions of Amgen Inc.’s Neupogen it has approved, giving the nod to Accofil from Accord Healthcare Ltd., of Haverhill, UK.

The product has recently been introduced under the brand Accofil Intas Pharmaceuticals has launched their first biosimilar, filgrastim, in Europe, through their wholly-owned subsidiary Accord ...